Related Experiment Video

Updated: May 27, 2026

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation
08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

ER and PI3K independently modulate endocrine resistance in ER-positive breast cancer

Brian A Van Tine1, Robert J Crowder, Matthew J Ellis

  • 1Division of Oncology, Department of Medicine, Washington University in Saint Louis, St. Louis, Missouri 63110, USA.

Cancer Discovery
|November 19, 2011
PubMed

Insights

Ligand-independent estrogen receptor (ER) activity drives endocrine therapy-resistant breast cancer growth via CDK4/E2F. Combining ER and PI3K pathway inhibitors shows promise for treating this aggressive cancer.

Area of Science:

  • Oncology
  • Endocrinology
  • Molecular Biology

Background:

  • Endocrine therapy-resistant estrogen receptor-positive (ER(+)) breast cancer is a leading cause of cancer mortality.
  • Understanding resistance mechanisms is crucial for developing effective treatments.

Purpose of the Study:

  • To investigate the role of ligand-independent ER activity in endocrine therapy resistance.
  • To explore the contribution of the phosphatidylinositol 3-kinase (PI3K) pathway to resistance.
  • To evaluate the preclinical rationale for combining ER and PI3K pathway inhibitors.

Main Methods:

  • The study by Miller and colleagues focused on identifying key molecular drivers of endocrine therapy resistance.
  • Investigated the interplay between estrogen receptor (ER) signaling and the PI3K pathway.
  • Utilized preclinical models to assess the efficacy of combined therapeutic inhibition.

Main Results:

  • Ligand-independent ER activity was found to promote breast cancer cell growth through the CDK4/E2F pathway.
  • The PI3K pathway was independently upregulated in endocrine therapy-resistant cells.
  • Preclinical data support the combination of fulvestrant (ER inhibitor) with PI3K inhibition.

Conclusions:

  • Ligand-independent ER activity and PI3K pathway activation are critical mechanisms in endocrine therapy-resistant ER(+) breast cancer.
  • Combined inhibition of ER and PI3K pathways presents a promising therapeutic strategy.
  • Clinical trials are underway to validate this combination therapy approach.

More Related Videos

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells16:24

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells

Published on: February 21, 2014

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...